Loading...
Market
Impact on Foresight Diagnostics' market share in cancer-detection by end of 2024?
2
Resolution / Starting Odds
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Market analysis reports, financial statements from Foresight Diagnostics
Story
Roche Sues Stanford, Foresight Over Genetic-Sequencing Trade Secrets in Cancer-Detection
Jul 4, 2024, 12:00 AM
Roche has filed a lawsuit against Stanford University and Foresight Diagnostics in California federal court, alleging that Foresight misused its genetic-sequencing trade secrets to develop competing cancer-detection products. Roche is seeking to force Foresight to hand over patent applications related to the disputed technology. This legal action underscores the competitive nature of the cancer-detection market and the importance of genetic-sequencing trade secrets in developing advanced diagnostic tools.
View original story
Similar markets
Less than 20% • 25%
20% to 30% • 25%
30% to 40% • 25%
More than 40% • 25%
Less than 10% • 33%
10% to 25% • 33%
More than 25% • 33%
0-10% • 25%
11-25% • 25%
26-50% • 25%
51%+ • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Increase by 5% or more • 33%
Fluctuate within ±5% • 33%
Decrease by 5% or more • 33%
New test leads market • 25%
Existing tests maintain dominance • 25%
Market share evenly distributed • 25%
Other outcome • 25%
Guardant Health becomes the market leader • 25%
Guardant Health is among the top 3 • 25%
Guardant Health remains in the top 5 • 25%
Guardant Health does not make it to the top 5 • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
PrecivityAD2™ dominates (>50%) • 25%
Sunbird Bio dominates (>50%) • 25%
Both share equally (~50% each) • 25%
Other diagnostic tests dominate • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
31%+ • 25%